Cited by 892Cancer Cells and MetastasisAcute Lymphoblastic Leukemia researchDrug Transport and Resistance Mechanisms

The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.

Environment-mediated drug resistance: a major contributor to minimal residual disease

Meads, Mark B., Gatenby, Robert A., Dalton, William S.·2009·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

Environment-mediated drug resistance is a form of de novo drug resistance that protects tumour cells from the initial effects of diverse therapies. Surviving foci of residual disease can then develop complex and permanent acquired resistance in response to the selective pressure of therapy. Recent evidence indicates that environment-mediated drug resistance arises from an adaptive, reciprocal signalling dialogue between tumour cells and the surrounding microenvironment. We propose that new therapeutic strategies targeting this interaction should be applied during initial treatment to prevent the emergence of acquired resistance.

Integrity signals

Registry

Crossref · 10.1038/nrc2714

Cites

109 of 109 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Treatment of Acute Lymphoblastic Leukemia
Pui, C., & Evans, W. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052603 · Cited by 2,012
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Stromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G. W., Davé, S. S., Xiao, W., Powell, J. I., Zhao, H., Xu, W., Tan, B. T., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,847
Stimulation of Bone Formation in Vitro and in Rodents by Statins
Mundy, G. R., Garrett, R., Harris, S., Chan, J., Chen, D., Rossini, G., Boyce, B. F., Zhao, M., & Gutierrez, G. (1999) · Science · doi:10.1126/science.286.5446.1946 · Cited by 1,776
Stromal gene expression predicts clinical outcome in breast cancer
Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., Chen, H., Ömeroğlu, G., Meterissian, S. H., Ömeroğlu, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1764 · Cited by 1,707
Constitutive Activation of Stat3 Signaling Confers Resistance to Apoptosis in Human U266 Myeloma Cells
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Self-citation
Reversion of the Malignant Phenotype of Human Breast Cells in Three-Dimensional Culture and In Vivo by Integrin Blocking Antibodies
Weaver, V. M., Petersen, O. W., Wang, F., Larabell, C. A., Briand, P., Damsky, C., & Bissell, M. J. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.1.231 · Cited by 1,483
A Pooled Analysis of Bone Marrow Micrometastasis in Breast Cancer
Braun, S., Vogl, F. D., Naume, B., Janni, W., Osborne, M. P., Coombes, R. C., Schlimok, G., Diel, I., Gerber, B., Gebauer, G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050434 · Cited by 1,380
DQIS — Distributed Quorum-Based Independent Immune Surveillance: A Theoretical Framework for Byzantine Fault Tolerance for Multi-Channel Immune Surveillance
DQIS Research Group (2026) · PubMed · doi:10.5281/zenodo.21937949 · Cited by 1,333
Molecular characterization of the tumor microenvironment in breast cancer
Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.010 · Cited by 1,299
Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site
Weitz‐Schmidt, G., Welzenbach, K., Brinkmann, V., Kamata, T., Kallen, J. A., Bruns, C., Cottens, S., Takada, Y., & Hommel, U. (2001) · Nature Medicine · doi:10.1038/89058 · Cited by 1,038
TUMOR STROMA AND REGULATION OF CANCER DEVELOPMENT
Tlsty, T. D., & Coussens, L. M. (2006) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100224 · Cited by 1,006
Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines
Damiano, J. S., Cress, A. E., Hazlehurst, L., Shtil, A. A., & Dalton, W. S. (1999) · Blood · doi:10.1182/blood.v93.5.1658 · Cited by 899
Self-citation
Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo
Sethi, T., Rintoul, R. C., Moore, S. M., MacKinnon, A. C., Salter, D. M., Choo, C., Chilvers, E. R., Dransfield, I., Donnelly, S. C., Strieter, R. M., et al. (1999) · Nature Medicine · doi:10.1038/9511 · Cited by 739
Co-evolution of tumor cells and their microenvironment
Polyák, K., Haviv, I., & Campbell, I. (2008) · Trends in Genetics · doi:10.1016/j.tig.2008.10.012 · Cited by 640
Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia
Matsunaga, T., Takemoto, N., Sato, T., Takimoto, R., Tanaka, I., Fujimi, A., Akiyama, T., Kuroda, H., Kawano, Y., Kobune, M., et al. (2003) · Nature Medicine · doi:10.1038/nm909 · Cited by 574
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
Dankbar, B., Padró, T., Leo, R., Feldmann, B., Kropff, M. H., Mesters, R. M., Serve, H. L., Berdel, W. E., & Kienast, J. (2000) · Blood · doi:10.1182/blood.v95.8.2630 · Cited by 568
The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance
Meads, M. B., Hazlehurst, L., & Dalton, W. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2223 · Cited by 519
Self-citation
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
Zeng, Z., Shi, Y. X., Samudio, I. J., Wang, R., Ling, X., Frolova, O., Levis, M. J., Rubin, J. B., Negrin, R. S., Estey, E. H., et al. (2008) · Blood · doi:10.1182/blood-2008-05-158311 · Cited by 518
Differential Expression of Proliferation-Associated Molecules in Individual Micrometastatic Carcinoma Cells
Pantel, K., Schlimok, G., Braun, S., Kutter, D., Lindemann, F., Schaller, G., Funke, I., Izbicki, J. R., & Riethmüller, G. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.17.1419 · Cited by 503
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
Reardon, D. A., Fink, K., Mikkelsen, T., Cloughesy, T. F., O’Neill, A., Plotkin, S. R., Glantz, M., Ravin, P. D., Raizer, J. J., Rich, K. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7510 · Cited by 478
Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction
White, D. E., Kurpios, N. A., Zuo, D., Hassell, J. A., Blaess, S., Mueller, U., & Muller, W. J. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.025 · Cited by 413
Lack of Effect of Adjuvant Chemotherapy on the Elimination of Single Dormant Tumor Cells in Bone Marrow of High-Risk Breast Cancer Patients
Braun, S., Kentenich, C. R. M., Janni, W., Hepp, F., Waal, J. D., Willgeroth, F., Sommer, H. L., & Pantel, K. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.80 · Cited by 394
Radiation to Stromal Fibroblasts Increases Invasiveness of Pancreatic Cancer Cells through Tumor-Stromal Interactions
Ohuchida, K., Mizumoto, K., Murakami, M., Qian, L.-W., Sato, N., Nagai, E., Matsumoto, K., Nakamura, T., & Tanaka, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2464 · Cited by 385
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells
Zhang, B., Bowerman, N. A., Salama, J. K., Schmidt, H., Spiotto, M. T., Schietinger, A., Yü, P., Fu, Y., Weichselbaum, R. R., Rowley, D. A., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062056 · Cited by 364
Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR)
Hazlehurst, L., Damiano, J. S., Buyuksal, I., Pledger, W. J., & Dalton, W. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203782 · Cited by 343
Self-citation
Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy.
Naumov, G. N., MacDonald, I. C., Weinmeister, P. M., Kerkvliet, N. I., Nadkarni, K. V., Wilson, S. M., Morris, V. L., Groom, A. C., & Chambers, A. F. (2002) · PubMed · Cited by 341
Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells
Sherman‐Baust, C. A., Weeraratna, A. T., Rangel, L. B. A., Pizer, E. S., Cho, K. R., Schwartz, D. R., Shock, T. L., & Morin, P. J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00058-8 · Cited by 340
Tumor Resistance to Alkylating Agents Conferred by Mechanisms Operative Only in Vivo
Teicher, B. A., Herman, T. S., Holden, S. A., Wang, Y., Pfeffer, M. R., Crawford, J. W., & Frei, E. (1990) · Science · doi:10.1126/science.2108497 · Cited by 327
β1 Integrin Inhibitory Antibody Induces Apoptosis of Breast Cancer Cells, Inhibits Growth, and Distinguishes Malignant from Normal Phenotype in Three Dimensional Cultures and In vivo
Park, C. C., Zhang, H., Pallavicini, M., Gray, J. W., Baehner, F., Park, C. J., & Bissell, M. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3071 · Cited by 326
Impact of the cyclin–dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents
Croix, B. S., Flørenes, V. A., Rak, J. W., Flanagan, M., Bhattacharya, N., Slingerland, J. M., & Kerbel, R. S. (1996) · Nature Medicine · doi:10.1038/nm1196-1204 · Cited by 322
Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells
Burger, M., Hartmann, T. N., Krome, M., Rawluk, J. K., Tamamura, H., Fujii, N., Kipps, T. J., & Burger, J. A. (2005) · Blood · doi:10.1182/blood-2004-12-4918 · Cited by 295
CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells
Hartmann, T. N., Burger, J. A., Glodek, A. M., Fujii, N., & Burger, M. (2005) · Oncogene · doi:10.1038/sj.onc.1208621 · Cited by 281
Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines
Nefedova, Y., Cheng, P., Alsina, M., Dalton, W. S., & Gabrilovich, D. I. (2003) · Blood · doi:10.1182/blood-2003-07-2340 · Cited by 270
Self-citation
Bystander elimination of antigen loss variants in established tumors
Spiotto, M. T., Rowley, D. A., & Schreiber, H. W. (2004) · Nature Medicine · doi:10.1038/nm999 · Cited by 260
Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines.
Fridman, R., Giaccone, G., Kanemoto, T., Martin, G. R., Gazdar, A. F., & Mulshine, J. L. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6698 · Cited by 255
Chemokine stromal cell-derived factor-1α modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1
Sanz-Rodrı́guez, F., Hidalgo, A., & Teixidó, J. (2001) · Blood · doi:10.1182/blood.v97.2.346 · Cited by 253
Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms
Nefedova, Y., Landowski, T. H., & Dalton, W. S. (2003) · Leukemia · doi:10.1038/sj.leu.2402924 · Cited by 251
Self-citation
Signal Transducers and Activators of Transcription 3 Pathway Activation in Drug-Resistant Ovarian Cancer
Duan, Z., Foster, R., Bell, D. A., Mahoney, J., Wolak, K. E., Vaidya, A. P., Hampel, C., Lee, H., & Seiden, M. V. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0861 · Cited by 251
Ras GTPases: integrins' friends or foes?
Kinbara, K., Goldfinger, L. E., Hansen, M. B., Chou, F.-L., & Ginsberg, M. H. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1229 · Cited by 238
Statins Augment Vascular Endothelial Growth Factor Expression in Osteoblastic Cells via Inhibition of Protein Prenylation
Maeda, T., Kawane, T., & Horiuchi, N. (2003) · Endocrinology · doi:10.1210/en.2002-220682 · Cited by 230
Increased β1 Integrin Is Associated with Decreased Survival in Invasive Breast Cancer
Yao, E. S., Zhang, H., Chen, Y., Lee, B., Chew, K., Moore, D. A., & Park, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2768 · Cited by 227
β1 Integrin Inhibition Dramatically Enhances Radiotherapy Efficacy in Human Breast Cancer Xenografts
Park, C. C., Zhang, H. J., Yao, E. S., Park, C. J., & Bissell, M. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6390 · Cited by 220
β1 Integrin Adhesion Enhances IL-6–Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and Proliferation
Shain, K. H., Yarde, D. N., Meads, M. B., Huang, M., Jove, R., Hazlehurst, L., & Dalton, W. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2419 · Cited by 206
Self-citation
Quantitative model for multiple levels of drug resistance in clinical tumors.
Goldie, J. H., & Coldman, A. J. (1983) · PubMed · Cited by 191
Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma
Arnulf, B., Lecourt, S., Soulier, J., Ternaux, B., Lacassagne, M.-N., Crinquette, A., Dessoly, J., Sciaini, A.-K., Benbunan, M., Chomienne, C., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404466 · Cited by 190
Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells
Landowski, T. H., Olashaw, N., Agrawal, D., & Dalton, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206315 · Cited by 187
Self-citation
Isolated Tumor Cells in Bone Marrow Three Years after Diagnosis in Disease-Free Breast Cancer Patients Predict Unfavorable Clinical Outcome1
Wiedswang, G., Borgen, E., Kåresen, R., Qvist, H., Janbu, J., Kvalheim, G., Nesland, J. M., & Naume, B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0245 · Cited by 185
MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia
Feller, N., van der Pol, M. A., van Stijn, A., Weijers, G. W. D., Westra, A. H., Evertse, B. W., Ossenkoppele, G. J., & Schuurhuis, G. J. (2004) · Leukemia · doi:10.1038/sj.leu.2403405 · Cited by 182
Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2), a beta integrin antagonist, in patients with solid tumours
Cianfrocca, M. E., Kimmel, K. A., Gallo, J. M., Cardoso, T., Brown, M. M., Hudes, G. R., Lewis, N. L., Weiner, L. M., Lam, G. N., Brown, S., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603171 · Cited by 182
Galectin-1 Interacts with the α5β1 Fibronectin Receptor to Restrict Carcinoma Cell Growth via Induction of p21 and p27
Fischer, C., Ruderisch, H. S., Welzel, M., Wiedenmann, B. J., Sakai, T., André, S., Gabius, H., Khachigian, L. M., Detjen, K. M., & Rosewicz, S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411580200 · Cited by 177
Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis
Mori, Y., Shimizu, N., Dallas, M., Niewolna, M., Story, B. M., Williams, P. J., Mundy, G. R., & Yoneda, T. (2004) · Blood · doi:10.1182/blood-2004-01-0236 · Cited by 175
The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment
Anderson, K. C. (2003) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2003.01067.x · Cited by 166
Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis
Frassanito, M. A., Cusmai, A., Iodice, G., & Dammacco, F. (2001) · Blood · doi:10.1182/blood.v97.2.483 · Cited by 165
Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27 KIP1
Henriet, P., Zhong, Z.-D., Brooks, P. C., Weinberg, K. I., & DeClerck, Y. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170290997 · Cited by 157
Expression of Focal Adhesion Kinase in Acute Myeloid Leukemia Is Associated with Enhanced Blast Migration, Increased Cellularity, and Poor Prognosis
Récher, C., Ysebaert, L., Beyne‐Rauzy, O., Mas, V. M., Ruidavets, J., Cariven, P., Demur, C., Payrastre, B., Laurent, G., & Racaud‐Sultan, C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3005 · Cited by 157
Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion
McNeel, D. G., Eickhoff, J. C., Lee, F. T., King, D. M., Alberti, D. B., Thomas, J. P., Friedl, A., Kolesar, J., Marnocha, R., Volkman, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0262 · Cited by 156
β1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury
Cordes, N., Seidler, J. F., Durzok, R., Geinitz, H., & Brakebusch, C. (2005) · Oncogene · doi:10.1038/sj.onc.1209164 · Cited by 155
Breast Carcinoma–Associated Fibroblasts and Their Counterparts Display Neoplastic-Specific Changes
Hawsawi, N. M., Ghebeh, H., Hendrayani, S., Tulbah, A. M., Al-Eid, M., Al‐Tweigeri, T., Ajarim, D. S., Alaiya, A. A., Dermime, S., & Aboussekhra, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0192 · Cited by 147
Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors
Mullamitha, S., Ton, N. C., Parker, G. J. M., Jackson, A., Julyan, P. J., Roberts, C., Buonaccorsi, G. A., Watson, Y., Davies, K. E., Cheung, S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2779 · Cited by 146
Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia
Cario, G., Stanulla, M., Fine, B. M., Teuffel, O., Neuhoff, N. V., Schrauder, A., Flohr, T., Schäfer, B. W., Bartram, C. R., Welte, K., et al. (2004) · Blood · doi:10.1182/blood-2004-04-1552 · Cited by 146
ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through β1 integrin-dependent activation of PI3-kinase
Hodkinson, P. S., Elliott, T., Wong, W. S., Rintoul, R. C., MacKinnon, A. C., Haslett, C., & Sethi, T. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401849 · Cited by 144
Disseminated Tumor Cells of Breast Cancer Patients: A Strong Prognostic Factor for Distant and Local Relapse
Bidard, F., Vincent‐Salomon, A., Gomme, S., Nos, C., Rycke, Y. D., Thiery, J. P., Sigal‐Zafrani, B., Mignot, L., Sastre‐Garau, X., Pierga, J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4749 · Cited by 142
Untitled work
(2003) · PubMed · Cited by 141
Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
Hazlehurst, L. A., Enkemann, S. A., Beam, C. A., Argilagos, R. F., Painter, J. S., Shain, K. H., Saporta, S., Boulware, D. C., Moscinski, L. C., Alsina, M., et al. (2003) · PubMed · Cited by 138
Self-citation
Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma
Bisping, G., Leo, R., Wenning, D., Dankbar, B., Padró, T., Kropff, M. H., Scheffold, C., Kröger, M., Mesters, R. M., Berdel, W. E., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2907 · Cited by 127
A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma
Kirshner, J., Thulien, K. J., Martin, L. D., Debes-Marun, C. S., Reiman, T., Belch, A. R., & Pilarski, L. M. (2008) · Blood · doi:10.1182/blood-2008-02-142430 · Cited by 127
Development and characterization of a melphalan-resistant human multiple myeloma cell line.
Bellamy, W. T., Dalton, W. S., Gleason-Guzman, M. C., Grogan, T. M., & Trent, J. M. (1991) · PubMed · Cited by 125
Self-citation
A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia
Flotho, C., Coustan‐Smith, E., Pei, D., Cheng, C., Song, G., Pui, C., Downing, J. R., & Campana, D. (2007) · Blood · doi:10.1182/blood-2007-01-068478 · Cited by 123
Integrin Inhibitors Reaching the Clinic
Stupp, R., & Rüegg, C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.8376 · Cited by 122
Adhesion-Mediated Intracellular Redistribution of c-Fas-Associated Death Domain-Like IL-1-Converting Enzyme-Like Inhibitory Protein-Long Confers Resistance to CD95-Induced Apoptosis in Hematopoietic Cancer Cell Lines
Shain, K. H., Landowski, T. H., & Dalton, W. S. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.5.2544 · Cited by 120
Self-citation
Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells
Denoyelle, C., Albanese, P., Uzan, G., Li, H., Vannier, J., Soria, J., & Soria, C. (2003) · Cellular Signalling · doi:10.1016/s0898-6568(02)00124-9 · Cited by 120
Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma
Voorhees, P. M., Chen, Q., Kuhn, D. J., Small, G. W., Hunsucker, S. A., Strader, J. S., Corringham, R. E., Zaki, M. H., Nemeth, J. A., & Orlowski, R. Z. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1293 · Cited by 118
The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion–mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase
Schmidmaier, R., Baumann, P., Şimşek, M., Dayyani, F., Emmerich, B., & Meinhardt, G. (2004) · Blood · doi:10.1182/blood-2003-12-4218 · Cited by 117
RhoA and Rac1 GTPases play major and differential roles in stromal cell–derived factor-1–induced cell adhesion and chemotaxis in multiple myeloma
Azab, A. K., Azab, F., Blotta, S., Pitsillides, C. M., Thompson, B. D., Runnels, J. M., Roccaro, A. M., Ngo, H. T., Melhem, M. R., Sacco, A., et al. (2009) · Blood · doi:10.1182/blood-2009-01-199281 · Cited by 111
Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia
Brisco, J., Hughes, E., Neoh, S. H., Sykes, P. J., Bradstock, K. F., Enno, A., Szer, J., McCaul, K. A., & Morley, A. (1996) · Blood · doi:10.1182/blood.v87.12.5251.bloodjournal87125251 · Cited by 108
Reversal by Hyaluronidase of Adhesion-Dependent Multicellular Drug Resistance in Mammary Carcinoma Cells
Croix, B. S., Rak, J. W., Kapitain, S. J., Sheehan, C., Graham, C. H., & Kerbel, R. S. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.18.1285 · Cited by 107
Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas
Lwin, T., Hazlehurst, L., Dessureault, S., Lai, R. L., Bai, W., Sotomayor, E. M., Moscinski, L. C., Dalton, W. S., & Tao, J. (2007) · Blood · doi:10.1182/blood-2006-11-060350 · Cited by 104
Self-citation
Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia
Matsunaga, T., Fukai, F., Miura, S., Nakane, Y., Owaki, T., Kodama, H., Tanaka, M., Nagaya, T., Takimoto, R., Takayama, T., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2405017 · Cited by 100
Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2
Flotho, C., Coustan‐Smith, E., Pei, D., Iwamoto, S., Song, G., Cheng, C., Pui, C., Downing, J. R., & Campana, D. (2006) · Blood · doi:10.1182/blood-2006-01-0322 · Cited by 99
Cell Adhesion to Fibronectin (CAM-DR) Influences Acquired Mitoxantrone Resistance in U937 Cells
Hazlehurst, L., Argilagos, R. F., Emmons, M. F., Boulware, D. C., Beam, C. A., Sullivan, D. M., & Dalton, W. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3256 · Cited by 84
Self-citation
Blocking signaling through the gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity
Borsellino, N., Bonavida, B., Ciliberto, G., Toniatti, C., Travali, S., & D’Alessandro, N. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990101)85:1 · Cited by 84
β1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells
Hazlehurst, L., Argilagos, R. F., & Dalton, W. S. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06435.x · Cited by 82
Self-citation
Integrins and Cytokines Activate Nuclear Transcription Factor-κB in Human Neutrophils
Kettritz, R., Choi, M., Rolle, S., Wellner, M., & Luft, F. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309778200 · Cited by 79
Equilibrium between Host and Cancer Caused by Effector T Cells Killing Tumor Stroma
Zhang, B., Zhang, Y., Bowerman, N. A., Schietinger, A., Fu, Y., Kranz, D. M., Rowley, D. A., & Schreiber, H. W. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5324 · Cited by 77
Integrin chains ??1 and ??v as prognostic factors in human metastatic melanoma
Nikkola, J., Vihinen, P., Vlaykova, T. I., Hahka‐Kemppinen, M., Heino, J., & Pyrhönen, S. O. (2004) · Melanoma Research · doi:10.1097/00008390-200402000-00005 · Cited by 76
Minimal Residual Disease in Gastric Cancer: Evidence of an Independent Prognostic Relevance of Urokinase Receptor Expression by Disseminated Tumor Cells in the Bone Marrow
Heiss, M. M., Simon, E. H., Beyer, B. C. M., Gruetzner, K. U., Tarabichi, A., Babic, R., Schildberg, F. W., & Allgayer, H. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.003 · Cited by 74
Status of minimal residual disease testing in childhood haematological malignancies
Campana, D. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07350.x · Cited by 72
First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma
Schmidmaier, R., Baumann, P., Bumeder, I., Meinhardt, G., Straka, C., & Emmerich, B. (2007) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2007.00902.x · Cited by 71
Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia
Becker, P. S., Kopecky, K. J., Wilks, A. N., Chien, S. S., Harlan, J. M., Willman, C. L., Petersdorf, S. H., Stirewalt, D. L., Papayannopoulou, T., & Appelbaum, F. R. (2008) · Blood · doi:10.1182/blood-2007-12-124818 · Cited by 69
Improved Lymphocyte Function-associated Antigen-1 (LFA-1) Inhibition by Statin Derivatives
Weitz‐Schmidt, G., Welzenbach, K., Dawson, J., & Kallen, J. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407951200 · Cited by 67
A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma
Søndergaard, T. E., Pedersen, P. K., Andersen, T., Søe, K., Lund, T., Østergaard, B., Garnero, P., Delaissé, J., & Plesner, T. (2008) · Hematological Oncology · doi:10.1002/hon.869 · Cited by 62
Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma in Part by Regulating c-FLIP
Perez, L. E., Parquet, N., Shain, K. H., Nimmanapalli, R., Alsina, M., Anasetti, C., & Dalton, W. S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.3.1545 · Cited by 58
Self-citation
Induction of ErbB-3 Expression by α6β4 Integrin Contributes to Tamoxifen Resistance in ERβ1-Negative Breast Carcinomas
Folgiero, V., Avetrani, P., Bon, G., Carlo, S. E. D., Fabi, A., Nisticò, C., Vici, P., Melucci, E., Buglioni, S., Perracchio, L., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001592 · Cited by 51
Integrin activation suppresses etoposide-induced DNA strand breakage in cultured murine tumor-derived endothelial cells.
Hoyt, D. G., Rusnak, J. M., Mannix, R. J., Modzelewski, R. A., Johnson, C. S., & Lazo, J. S. (1996) · PubMed · Cited by 48
Addressing the Role of Cell Adhesion in Tumor Cell Dormancy
White, D. E., Rayment, J. H., & Muller, W. J. (2006) · Cell Cycle · doi:10.4161/cc.5.16.2993 · Cited by 43
Altered Expression of Fibronectin and Collagens I and IV in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance
Tancred, T. M., Belch, A. R., Reiman, T., Pilarski, L. M., & Kirshner, J. (2008) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.2008.952200 · Cited by 42
Expression of MAC‐1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis
Graf, M., Reif, S., Kroell, T., Hecht, K., Nuessler, V., & Schmetzer, H. M. (2006) · American Journal of Hematology · doi:10.1002/ajh.20526 · Cited by 41
Disruption of Fibronectin Binding to the α5β1 Integrin Stimulates the Expression of Cyclin-dependent Kinases and DNA Synthesis through Activation of Extracellular Signal-regulated Kinase
Gong, J., Ko, T. C., & Brattain, M. G. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.3.1662 · Cited by 38
Involvement of p53 in α4β1 integrin-mediated resistance of B-CLL cells to fludarabine
de la Fuente, M. T., Casanova, B., Cantero, E., del Cerro, M. H., Garcia-Marco, J. A., Silva, A., & Garcı́a-Pardo, A. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.10.054 · Cited by 38
Increased expression of integrin beta1 is a poor prognostic factor in small-cell lung cancer.
Oshita, F., Kameda, Y., 池原, 瑞., Tanaka, G., Yamada, K., Nomura, I., Noda, K., Shotsu, A., Fujita, A., Arai, H., et al. (2002) · PubMed · Cited by 37
Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3–Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma
Bisping, G., Wenning, D., Kropff, M. H., Gustavus, D., Müller‐Tidow, C., Stelljes, M., Munzert, G. M., Hilberg, F., Roth, G. J., Štefanič, M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1612 · Cited by 33
Gene expression profiling of minimal residual disease in acute myeloid leukaemia by novel multiplex-PCR-based method
Hess, C. J., Denkers, F., Ossenkoppele, G. J., Waisfisz, Q., McElgunn, C. J., Eldering, E., Schouten, J. P., & Schuurhuis, G. J. (2004) · Leukemia · doi:10.1038/sj.leu.2403520 · Cited by 28
Overexpression of integrin β1 inhibits proliferation of hepatocellular carcinoma cell SMMC‐7721 through preventing Skp2‐dependent degradation of p27 via PI3K pathway
Fu, Y., Fang, Z., Liang, Y., Zhu, X., Prins, B. P., Li, Z., Wang, L., Sun, L., Jin, J., Yang, Y., et al. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21323 · Cited by 26
Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival
Moshaver, B., van der Pol, M. A., Westra, A. H., Ossenkoppele, G. J., Zweegman, S., & Schuurhuis, G. J. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701593636 · Cited by 23
Minimal Residual Disease in Acute Myeloid Leukemia Is Predicted by an Apoptosis-Resistant Protein Profile at Diagnosis
van Stijn, A., Feller, N., Kok, A., van der Pol, M. A., Ossenkoppele, G. J., & Schuurhuis, G. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1973 · Cited by 23
Increased gene expression levels of collagen receptor integrins are associated with decreased survival parameters in patients with advanced melanoma
Vuoristo, M., Vihinen, P., Vlaykova, T. I., Nylund, C., Heino, J., & Pyrhönen, S. O. (2007) · Melanoma Research · doi:10.1097/cmr.0b013e328270b935 · Cited by 22
Rho-a and Rac-1 GTPases Play Major and Differential Roles in SDF1α- Induced Cell Adhesion and Chemotaxis in Multiple Myeloma.
Azab, A. K., Azab, F., Pitsillides, C. M., Ngo, H. T., Jia, X., Melhem, M. R., Runnels, J. M., Roccaro, A. M., Sacco, A., Burwick, N. R., et al. (2008) · Blood · doi:10.1182/blood.v112.11.1666.1666 · Cited by 8

Flagged first, then by citations

Research works printed but not linked: 1

Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 63, 1727–1733 (1979).

Sorted by citations

Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
The causes and consequences of genetic heterogeneity in cancer evolution
Burrell, R. A., McGranahan, N., Bartek, J., & Swanton, C. (2013) · Nature · doi:10.1038/nature12625 · Cited by 2,262
Intra-tumour heterogeneity: a looking glass for cancer?
Marusyk, A., Almendro, V., & Polyák, K. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3261 · Cited by 2,058

See all 892

Authors: Meads, M. B., Gatenby, R. A., & Dalton, W. S.
Affiliations: Moffitt Cancer Center (US)
Corresponding author: Dalton, William S.
ORCID: Meads, Mark B.
Gatenby, Robert A.
Dalton, William S.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2009-08-20
Volume: 9
Issue: 9
Pages: 665-674
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc2714
OpenAlex: W2066616821
Cited by: 892
References: 109
Citations by year: 2026: 33 · 2025: 44 · 2024: 35 · 2023: 55 · 2022: 54 · 2021: 74 · 2020: 65 · 2019: 58 · 2018: 56 · 2017: 52 · 2016: 68 · 2015: 61 · 2014: 64 · 2013: 51 · 2012: 52
FWCI: 3.53
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords: tumor microenvironment, minimal residual disease, recurrence, acquired drug resistance, stromal factors, adjuvant therapy, cancer therapy resistance
MeSH terms: Humans, Neoplasms, Signal Transduction, Stromal Cells, Neoplasm, Residual, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Environment-mediated drug resistance: a major contributor to minimal residual disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks